AUG 7, 2026 · PHASE 1/2 TRIAL
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
ClinicalTrials.gov
This is a clinical trial registry record for a planned first-in-human Phase 1/2 study with no results posted; enrollment has not yet begun.
Reported
Planned enrollment250
Phase 1 primary endpointNumber of participants with dose-limiting t…
Phase 1 primary endpointFrequency of treatment-emergent adverse eve…